Cellular Biomedicine Raises $30.6 Million from Sailing Capital

Cellular Biomedicine, a China-US biopharma, announced a $30.6 million investment from Sailing Capital Overseas. Sailing Capital is a Shanghai-Hong Kong PE investor focused on China cross-border situations. CBMG is developing a CAR-T immunotherapy for cancer indications, which it acquired from Beijing 's PLA General Hospital (the 301) in 2015. The immunotherapy is currently being tested in three China clinical trials. CBMG's latest funding brings its cash position to about $60 million. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //